NVAX Q3 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M-16.6% YoY

Gross Profit

$49M69.5% margin

Operating Income

-$178M-252.7% margin

Net Income

-$202M-287.3% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

-70.6%

Cash Flow

Operating Cash Flow

$108M

Free Cash Flow

$106M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.3B

Stockholders' Equity

-$157M

Cash & Equivalents

$268M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$85M	-16.6%
Gross Profit	$49M	$24M	+104.9%
Operating Income	-$178M	-$134M	-32.8%
Net Income	-$202M	-$121M	-66.8%

Revenue Segments

Supply Sales

$14M51%

Product

$13M50%

Nuvaxovid Sales

-$332,000-1%

Geographic Segments

UNITED STATES

$57M81%

Rest of the World

$13M18%

Europe

$655,0001%